USPTO Examiner POPA ILEANA - Art Unit 1633

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19029962IONIZABLE CATIONIC LIPIDSJanuary 2025August 2025Allow610NoNo
18797392IONIZABLE CATIONIC LIPIDSAugust 2024February 2025Allow710NoNo
18752372METHOD FOR SIMPLY CONSTRUCTING TWO-COMPONENT VIRAL VECTOR AND RELATED APPLICATIONS THEREOFJune 2024June 2025Allow1111NoNo
18602410IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERYMarch 2024January 2026Allow2210NoNo
18463155TELOMERASE REVERSE TRANSCRIPTASE-BASED THERAPIESSeptember 2023January 2026Abandon2810NoNo
18327728POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS FOR THE TREATMENT OF PROPIONIC ACIDEMIAJune 2023February 2026Allow3310NoNo
18306673Tracking and Manipulating Cellular RNA via Nuclear Delivery of CRISPR/CAS9April 2023September 2025Abandon2811NoNo
18191718COMPOSITION TO INCREASE CELLULARLONGEVITYMarch 2023March 2025Abandon2331NoNo
18112239METHODS FOR ANALYSIS OF SOMATIC MOBILE ELEMENTS, AND USES THEREOFFebruary 2023January 2026Abandon3511NoNo
18162104WT1 VACCINEJanuary 2023February 2026Allow3730NoNo
18000838NUCLEIC ACID MOLECULE TARGETING MITF GENE AND USE THEREOFDecember 2022March 2026Abandon3901NoNo
17923470IMPROVED COMPOSITIONS FOR CFTR MRNA THERAPYNovember 2022December 2025Allow3710NoNo
18049210CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USESOctober 2022December 2025Allow3810NoNo
17970170IMMUNOSTIMULATORY COMPOSITIONSOctober 2022February 2026Abandon4010NoNo
17964523VIRAL VECTOR DOSING PROTOCOLSOctober 2022March 2026Abandon4110NoNo
17938816In vivo targeting of Fibrosis by anti-CD5-targeted FAP-CAR T mRNA-LNPOctober 2022August 2025Abandon3451NoNo
17938008METHODS FOR ENGINEERING NON-NEURONAL CELLS INTO NEURONS AND USING NEWLY ENGINEERED NEURONS TO TREAT NEURODEGENERATIVE DISEASESOctober 2022December 2025Abandon3901NoNo
17939707Immuno-Oncolytic TherapiesSeptember 2022July 2025Allow3420YesNo
17900233COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNAAugust 2022September 2025Abandon3620NoNo
17883973COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDSAugust 2022April 2025Allow3220NoNo
17759687MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOFJuly 2022January 2026Abandon4101NoNo
17813984POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIAJuly 2022March 2025Allow3210NoNo
17813304MODULATING GAMMA-C-CYTOKINE ACTIVITYJuly 2022September 2025Abandon3820NoNo
17867128METHODS AND MEANS FOR INDUCING AN IMMUNE RESPONSEJuly 2022February 2025Abandon3110NoNo
17859470DELIVERY OF GENE THERAPY TREATMENTSJuly 2022March 2025Allow3310NoNo
17859564THERAPEUTIC AGENTS COMPRISING ONCOLYTIC VACCINIA VIRUSES AND NK CELLS, AND USES THEREOF FOR DRUGS FOR TREATMENT OF TUMORS AND/OR CANCERSJuly 2022September 2024Abandon2710NoNo
17845660ANELLOVIRUS COMPOSITIONS AND METHODS OF USEJune 2022February 2025Allow3220NoNo
17749012TARGETED DISRUPTION OF THE T CELL RECEPTORMay 2022December 2025Abandon4320NoNo
17721063OCULAR DELIVERY OF THERAPEUTIC AGENTSApril 2022September 2023Abandon1711NoNo
17705803MESSENGER RNA VACCINES AND USES THEREOFMarch 2022March 2025Allow3610NoNo
17699035CORONAVIRUS VACCINEMarch 2022September 2023Abandon1820YesYes
17686245USE OF iNOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTUREMarch 2022February 2026Abandon4730YesNo
17582289MUTANT FACTOR VIII COMPOSITIONS AND METHODSJanuary 2022December 2025Abandon4710NoNo
17570962METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLSJanuary 2022June 2025Abandon4201NoNo
17560197LIVER SPECIFIC DELIVERY OF MESSENGER RNADecember 2021June 2023Abandon1720NoNo
17560195LIVER SPECIFIC DELIVERY OF MESSENGER RNADecember 2021December 2023Abandon2420NoYes
17558555LIVER SPECIFIC DELIVERY OF MESSENGER RNADecember 2021April 2023Abandon1620NoNo
17620331SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHADecember 2021December 2025Abandon4801NoNo
17553603RNA-NANOSTRUCTURED DOUBLE ROBOTS AND METHODS OF USE THEREOFDecember 2021January 2025Allow3710NoNo
17547498BACTERIA ENGINEERED TO TREAT DISORDERS INVOLVING THE CATABOLISM OF A BRANCHED CHAIN AMINO ACIDDecember 2021August 2024Abandon3201NoNo
17541018CD25 PRE-SELECTIVE COMBINATION ANTI-HIV VECTORS, TARGETING VECTORS, AND METHODS OF USEDecember 2021September 2024Abandon3401NoNo
17610942COMPOSITIONS AND METHODS FOR TARGETING MULTINUCLEATED CELLSNovember 2021March 2026Abandon5221YesNo
17517967AGENTS FOR PROMOTING TISSUE REGENERATION BY RECRUITING BONE MARROW MESENCHYMAL STEM CELLS AND/OR PLURIPOTENT STEM CELLS INTO BLOODNovember 2021March 2025Abandon4121NoNo
17603220Correction of Beta-Thalassemia Phenotype by Genetically Engineered Hematopoietic Stem CellOctober 2021February 2026Abandon5231NoNo
17488608TRANSGENIC PIG ISLETS AND USES THEREOF FOR TREATING DIABETESSeptember 2021March 2025Abandon4110NoNo
17489652ANELLOVIRUS COMPOSITIONS AND METHODS OF USESeptember 2021March 2022Allow610NoNo
17487562COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDSSeptember 2021July 2024Allow3410NoNo
17438135OPTIMISED RAG1 DEFICIENT GENE THERAPYSeptember 2021June 2025Allow4511YesNo
17396090FORMULATIONS FOR HIGHLY PURIFIED VIRAL PARTICLESAugust 2021December 2025Abandon5231NoNo
17426613TREATMENT OF AGING OR AGE-RELATED DISORDERS USING XBP1July 2021June 2025Abandon4610NoNo
17382757STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDSJuly 2021February 2025Abandon4320NoNo
17376135PROGRAMMABLE, SELF-ASSEMBLING PATCHED NANOPARTICLES, AND ASSOCIATED DEVICES, SYSTEMS AND METHODSJuly 2021July 2024Abandon3611NoNo
17371386MATERIALS AND METHODS FOR TREATMENT OF HEREDITARY HAEMOCHROMATOSISJuly 2021August 2024Allow3821NoNo
17368947DUAL VECTOR FOR INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUSJuly 2021September 2023Abandon2710NoNo
17347498TERTIARY AMINO LIPIDATED CATIONIC PEPTIDES FOR NUCLEIC ACID DELIVERYJune 2021February 2023Allow2021YesNo
17343071METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLSJune 2021July 2024Abandon3711NoNo
17339607TRANSPOSITION OF NUCLEIC ACIDS INTO EUKARYOTIC GENOMES WITH A TRANSPOSASE FROM HELIOTHISJune 2021May 2025Allow4731YesNo
17325292TARGETED NANOPARTICLESMay 2021December 2025Abandon5511NoNo
17321328METHOD OF PREPARING NUCLEASE-RESISTANT DNA-INORGANIC HYBRID NANOFLOWERSMay 2021February 2025Abandon4510NoNo
17294296COMPOSITIONS AND METHODS FOR THE TREATMENT OF SMOOTH MUSCLE DYSFUNCTIONMay 2021November 2024Abandon4210NoNo
17294350RELAXIN RECEPTOR 1 FOR USE IN TREATMENT AND PREVENTION OF HEART FAILUREMay 2021August 2025Abandon5121NoNo
17244445METHODS OF DELIVERING OLIGONUCLEOTIDES TO IMMUNE CELLSApril 2021May 2024Abandon3611NoNo
17219116DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATIONMarch 2021September 2023Abandon3010NoNo
17189368TELOMERASE REVERSE TRANSCRIPTASE-BASED THERAPIESMarch 2021October 2025Abandon5550NoNo
17189120CHIMERIC NUCLEIC ACID MOLECULES WITH NON-AUG TRANSLATION INITIATION SEQUENCES AND USES THEREOFMarch 2021September 2024Abandon4301NoNo
17174505NEOANTIGENS EXPRESSED IN OVARIAN CANCER AND THEIR USESFebruary 2021February 2024Allow3611NoNo
17170785PEPTIDE/LIPID-ASSOCIATED NUCLEIC ACIDS (PLANA) FOR NUCLEIC ACID DELIVERYFebruary 2021November 2024Abandon4531NoNo
17165159COMPOSITIONS AND METHODS FOR INDUCING SCARRING BY PERI-TUMORAL CELLSFebruary 2021July 2023Abandon3001NoNo
17154309POLYNUCLEOTIDES ENCODING GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF GALACTOSEMIA TYPE 1January 2021October 2024Allow4522NoNo
17142731LIPID NANOPARTICLE MRNA VACCINESJanuary 2021March 2025Abandon5021NoNo
17124462LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERY OF MRNA AND LONG NUCLEIC ACIDSDecember 2020August 2024Abandon4452YesNo
17099140COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TET2 ENGINEERED T CELL THERAPYNovember 2020August 2025Abandon5761YesYes
17083771PROCESS FOR THE PREPARATION OF ERYTHROCYTES LOADED WITH ONE OR MORE SUBSTANCES OF PHARMACEUTICAL INTEREST AND SO OBTAINED ERYTHROCYTESOctober 2020January 2025Allow5121NoYes
17051583ENHANCED BCL11A RNP / CRISPR DELIVERY & EDITING USING A 3XNLS-CAS9October 2020September 2025Allow5831NoNo
17050918HIGHLY KNOTTED MOLECULAR TOPOLOGIES FROM SINGLE-STRANDED NUCLEIC ACIDSOctober 2020February 2025Allow5221NoNo
17072611Membrane-Receiver Complex TherapeuticsOctober 2020July 2023Abandon3301NoNo
17067101METHOD OF TREATING IMMUNOTHERAPY NON-RESPONDERS WITH AN AUTOLOGOUS CELL THERAPYOctober 2020January 2025Abandon5121NoYes
17033166VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDERSeptember 2020September 2024Allow4740YesNo
17029436COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTSSeptember 2020January 2025Allow5240NoNo
17021555NUCLEASE-MEDIATED REGULATION OF GENE EXPRESSIONSeptember 2020November 2023Allow3820NoNo
17017150COMPOSITIONS AND METHODS FOR TREATING MPSISeptember 2020February 2025Abandon5321NoNo
17015995METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPYSeptember 2020May 2024Abandon4411NoNo
16979138METHODS AND COMPOSITIONS FOR USE OF TUMOR SELF-ANTIGENS IN ADOPTIVE IMMUNOTHERAPYSeptember 2020March 2025Allow5431NoNo
16977385BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE/RECEPTOR PAIRSSeptember 2020August 2024Abandon4711NoNo
16999459NEURAL STEM CELL DELIVERY OF THERAPEUTIC AGENTSAugust 2020July 2025Allow5941YesNo
16990356Compositions for In Vitro Amplification of Nucleic AcidsAugust 2020September 2023Abandon3720NoNo
16983121IONIZABLE CATIONIC LIPIDSAugust 2020January 2024Allow4220NoNo
16947427NOVEL USE OF GIT HAVING ANTI-SENESCENCE ACTIVITYJuly 2020December 2025Abandon6041NoNo
16941148REGULATABLE CHIMERIC ANTIGEN RECEPTORJuly 2020July 2023Abandon3601NoNo
16938242METHODS FOR THE TREATMENT OF PROSTATE CANCERJuly 2020September 2023Abandon3820NoNo
16914567Targeted intracellular delivery of antiviral agentsJune 2020December 2022Abandon3010NoNo
16914422NANOPARTICLES INCLUDING A GLATIRAMOID USEFUL IN POLYNUCLEOTIDE DELIVERYJune 2020November 2022Abandon2921YesNo
16904493METHODS AND COMPOSITIONS FOR IMPROVED HOMOLOGY DIRECTED REPAIRJune 2020November 2024Abandon5331YesNo
16954458RNA-NANOSTRUCTURED DOUBLE ROBOTS AND METHODS OF USE THEREOFJune 2020September 2021Allow1521NoNo
16772759METHODS AND COMPOSITIONS FOR TREATING CANCER USING EXOSOMES-ASSOCIATED GENE EDITINGJune 2020January 2026Abandon6040NoYes
16770012MICRO- AND NANONEEDLES FOR PLANT AND OTHER CELL PENETRATIONJune 2020May 2023Abandon3622NoNo
16765632POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS FOR THE TREATMENT OF PROPIONIC ACIDEMIAMay 2020January 2025Allow5631NoNo
16872679Optically Transparent Silk HydrogelsMay 2020March 2024Allow4620NoYes
16864492Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal BarrierMay 2020April 2023Abandon3601NoNo
16758824METHOD FOR INCREASING FETAL HEMOGLOBIN EXPRESSION LEVELApril 2020April 2024Abandon4831NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner POPA, ILEANA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
82
Examiner Affirmed
58
(70.7%)
Examiner Reversed
24
(29.3%)
Reversal Percentile
45.8%
Lower than average

What This Means

With a 29.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
304
Allowed After Appeal Filing
40
(13.2%)
Not Allowed After Appeal Filing
264
(86.8%)
Filing Benefit Percentile
15.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 13.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner POPA, ILEANA - Prosecution Strategy Guide

Executive Summary

Examiner POPA, ILEANA works in Art Unit 1633 and has examined 959 patent applications in our dataset. With an allowance rate of 18.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 48 months.

Allowance Patterns

Examiner POPA, ILEANA's allowance rate of 18.9% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by POPA, ILEANA receive 3.26 office actions before reaching final disposition. This places the examiner in the 91% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by POPA, ILEANA is 48 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +21.4% benefit to allowance rate for applications examined by POPA, ILEANA. This interview benefit is in the 66% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 4.9% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 13.6% of cases where such amendments are filed. This entry rate is in the 14% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 39.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 47.8% of appeals filed. This is in the 13% percentile among all examiners. Of these withdrawals, 44.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 82.5% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.0% of allowed cases (in the 68% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 13.3% of allowed cases (in the 91% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.